Immudex
Immudex is a Danish biotechnology company that develops and commercializes Dextramer® MHC multimer reagents for detecting and characterizing antigen-specific T cells, B cells, and CAR cells. It serves cell therapy developers, vaccine researchers, immuno-oncology programs, and clinical laboratories with research and GMP-grade products.
- Company typePrivate
- Founded2009
- HeadquartersVirum, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immudex does
Immudex ApS is a Danish-headquartered (Virum) biotechnology company founded in 2009 that develops and commercializes reagents for the quantitation, characterization, and generation of antigen-specific immune cells. Its core technology is the Dextramer® platform — MHC multimers assembled on a dextran backbone that provide high-avidity detection of antigen-specific T cells, B cells, CAR cells, and non-conventional T cell subsets (MAIT, NKT, NK) across flow cytometry, NGS, and single-cell multi-omics workflows. The portfolio is anchored by MHC I and MHC II Dextramer® reagents for flow cytometry, dCODE® Dextramer® (HiT, RiO, 10x formats) for NGS and BD Rhapsody™ / 10x Chromium integration, Klickmer®/dCODE Klickmer® for customizable B cell detection, CAR Dextramer® (CD19, BCMA, MSLN), and Xynapse™-T non-cellular scaffolds for antigen-specific T cell activation. Supporting products include U-Load® self-assembly reagents, easYmers® peptide-receptive monomers (via immunAware), disease-specific panels (including SARS-CoV-2), MR1/CD1d/HLA-E/HLA-G reagents, plus clinical-grade Dextramer® GMP and MHC Monomers (GMP) under ISO 13485:2016 certification and 21 CFR Part 820 compliance.
The company monetizes through one-time reagent sales, professional services (custom alleles, TCR solutions, pMHC binding screening, easYmers® on dextran, GMP production establishment), and clinical-grade reagent supply, with most pricing on a quote basis. Distribution is hybrid: a direct e-commerce storefront and dedicated field sales/product information/technical support teams, augmented by regional distributors across 16 countries in Europe, Americas, and Asia/Pacific including a dedicated Chinese-language channel. Customer segments span cell therapy developers (CAR-T/TCR-T), vaccine developers, immuno-oncology researchers, infectious disease researchers, academic laboratories, and clinical/medical device manufacturers — with named enterprise users including Immatics and Symphogen/Servier.
The intellectual property base is broad: granted dCODE® patents in the US, EU, Japan, Australia, Canada, Singapore, and Hong Kong, plus registered trademarks (Dextramer®, easYmers®, Xynapse™) and a catalog of 65+ alleles across human, primate, and mouse species. Strategic partnerships include Parean Biotechnologies (10x Genomics Certified Service Provider) and Ardigen (AI CRO for multi-omics data analysis), positioning Immudex within an end-to-end immune-monitoring workflow from reagent to bioinformatics insight.
Immudex firmographics
Firmographics- Name
- Immudex
- Legal name
- Immudex ApS
- Website
- https://immudex.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Immudex is a Danish biotechnology company that develops and commercializes Dextramer® MHC multimer reagents for detecting and characterizing antigen-specific T cells, B cells, and CAR cells. It serves cell therapy developers, vaccine researchers, immuno-oncology programs, and clinical laboratories with research and GMP-grade products.
- Ownership category
- akta.pro rank
Immudex industry classification
Industry- Product category
- Immune Monitoring Reagents
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Immudex is headquartered
LocationHeadquarters
- HQ city
- Virum
- HQ country
- Denmark
- HQ region
- Europe
Offices3 records
Markets served
Immudex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Research Reagent Sales: Sale of standardized Dextramer® reagents including MHC I/II Dextramer®, dCODE Dextramer®, Klickmer®, CAR Dextramer®, and related products for flow cytometry and multi-omics applications. Products available in various test sizes with multiple fluorophore options (PE, APC, FITC, BV421).
- Custom Solutions and Services: Consulting and manufacturing services including custom alleles, custom Dextramer® reagents, TCR solutions, pMHC binding screening, easYmers® on dextran, and GMP production establishment. Projects assessed individually and matched to customer requirements.
- Clinical-Grade Reagents: GMP-grade MHC Dextramer® reagents and MHC monomers for lot-release testing of T cell therapies, clinical trials, and medical device manufacturing. Produced under ISO 13485:2016 certification with comprehensive documentation.
- Xynapse™ Reagent Sales: Sale of Xynapse™-T reagents for T cell stimulation and expansion, available in 100μl and 250μl sizes with pMHC/aCD28 configuration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | CAR Dextramer® catalog products - 50 test sizes with PE fluorophore |
| Unit Pricing | Pay-as-you-go | Xynapse™-T reagents - 100μl and 250μl sizes |
| Unit Pricing | Pay-as-you-go | easYmers® on Dextran - multiple test sizes and fluorophore options |
| Other | Multi-year contract | Custom Solutions and Services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels10 records
Immudex product offering
Product offeringCore offering
Immudex develops, manufactures, and commercializes Dextramer®-based biological reagents and related custom services for the detection, characterization, and generation of antigen-specific immune cells. Its portfolio spans flow cytometry reagents, DNA-barcoded reagents for NGS and single-cell multi-omics, GMP-grade clinical reagents, and T cell stimulation scaffolds, supported by a custom solutions team that develops new alleles, TCR reagents, and tailored assays for cell therapy developers, vaccine researchers, and academic immunology laboratories.
Product overview
Immudex is a biotechnology company offering a comprehensive portfolio of Dextramer® reagents and services for immune-monitoring research and clinical applications. The core product line includes MHC I and II Dextramer® reagents for flow cytometry, dCODE Dextramer® products for NGS and single-cell multi-omics analysis, Klickmer® and dCODE Klickmer® for B-cell and customizable detection, CAR Dextramer® for CAR cell detection, and Xynapse™-T for T-cell stimulation. Supporting products include U-Load® reagents for lab-built Dextramers, Immudex Monomers (easYmers® MHC I, U-Load® MHC II, Soluble TCR Monomers), disease-specific panels (SARS-CoV-2, cancer, infectious disease), and MR1, CD1d, HLA-E/G products for non-conventional T cells and NK cells. Clinical-grade offerings include Dextramer® CMV Kit (IVD), Dextramer® GMP, and MHC Monomers (GMP). Custom Solutions and Services provide TCR Solutions, Custom Alleles, easYmers® on Dextran, pMHC Binding Screening, and Custom CAR Dextramer® for tailored research needs.
Differentiator
Problem solved
Functional benefit
Products and services
- MHC I Dextramer® - Flow Cytometry Ready-to-use Dextramer® reagents for detection and quantification of antigen-specific CD8+ T cells by flow cytometry, delivering a strong signal-to-noise ratio for immune monitoring research.
- MHC II Dextramer® - Flow Cytometry Ready-to-use Dextramer® reagents for detection and quantification of antigen-specific CD4+ T cells by flow cytometry.
- dCODE Dextramer® - NGS/Multi-omics MHC Dextramer® reagents with unique DNA barcodes for analysis of antigen-specific T cells by NGS or single-cell multi-omics, offered in HiT (bulk NGS), RiO (BD Rhapsody™), and 10x (10x Chromium) formats.
- dCODE Klickmer® Customizable analysis reagents for detection of antigen-specific immune cells by NGS or single-cell multi-omics, enabling B-cell specificity mapping and antibody discovery workflows.
- Klickmer® Dextramer® technology combined with flexible customization for detecting antigen-specific B cells and other immune cells by flow cytometry.
- U-Load® Build-your-own Dextramer® reagent system allowing researchers to assemble MHC monomers with their choice of peptide specificity in their own laboratory.
- U-Load dCODE Dextramer® Flexible dCODE Dextramer® reagents that users can build with their choice of MHC complex and peptide for NGS or single-cell multi-omics analysis.
- CAR Dextramer® Rapid one-step staining reagents for sensitive and robust detection of CAR cells, with catalog products covering CD19, BCMA, and mesothelin targets for CAR-T cell therapy development.
- Xynapse™-T - T Cell Stimulation Non-cellular antigen-presenting scaffolds providing potent two-signal activation and expansion of T cells and TCR-engineered T cells by mimicking the TCR immunological synapse through pMHC-TCR interaction and CD28 engagement.
- MR1 Products Reagents for reliable detection and characterization of antigen-specific MAIT (mucosal-associated invariant T) cells using MR1 Dextramer® technology.
- CD1d Products Reagents for detection and characterization of CD1d-restricted NKT (natural killer T) cells using CD1d Dextramer® technology.
- HLA-E and HLA-G Products Reagents for investigation of antigen-specific NK cell immune responses using HLA-E and HLA-G Dextramer® products.
- Immudex Monomers High-quality MHC monomers, including easYmers® MHC I (powered by immunAware), U-Load® MHC II monomers, and Soluble TCR Monomers, for flexible applications including multimer assembly, T-cell stimulation, and TCR characterization.
- Dextramer® Controls Quality control reagents for accurate distinction between background and antigen-specific staining, recommended for optimization of gating or sorting of positive cells.
- Disease Panels - Flow Cytometry Pre-defined panels of selected Dextramer® reagents for disease-specific immune monitoring in cancer and infectious diseases, enabling detection and quantification of antigen-specific T cells without missing low-affinity cells.
- SARS-CoV-2 Dextramer® Reagents Pre-defined SARS-CoV-2 Dextramer® Panels with curated selection of validated T-cell epitopes for monitoring T-cell immunity in COVID-19 research.
- Dextramer® - In Situ Staining Reagents for visualization of tissue-specific immunity by tracking spatial distribution of antigen-specific immune cells in tissue via direct or indirect staining.
- Dextramer® CMV Kit - In Vitro Diagnostics In vitro diagnostic reagent for monitoring cytomegalovirus-specific T cells, supporting transplantation patient monitoring.
- Dextramer® GMP Clinical-grade MHC Dextramer® reagents produced in compliance with ISO 13485 and 21 CFR 820 for lot-release testing of T cell therapies.
- MHC Monomers (GMP) GMP-grade MHC monomers for applications requiring excellent quality reagents with high documentation, including LDT components, medical devices, clinical trials (GC(L)P), and manufacturing/QC of pharmaceutical products.
- Custom MHC Dextramer® Custom-designed Dextramer® reagents with specific alleles and peptide specificities tailored to unique research requirements.
- TCR Solutions Custom production of TCR candidates as Soluble TCR Monomers or TCR Dextramer® reagents, supporting TCR discovery, validation, and characterization.
- Custom Alleles Manufacturing of new alleles on request, including feasibility assessment, design, development, and quality-controlled delivery of custom Dextramer® reagents or monomers.
- easYmers® on Dextran Custom service loading user-specified class I alleles with peptides of interest and assembling MHC monomers on a dextran backbone for ready-to-use Dextramer® reagents.
- pMHC Binding Screening Service evaluating the potential of user-specified peptides and alleles to form stable peptide-MHC complexes using semi-quantitative bead-based assays for epitope discovery and validation.
- Custom CAR Dextramer® Custom CAR Dextramer® reagents produced to match user-specified target antigens for CAR cell detection and characterization.
- Dextramer® BV421 Dextramer® reagent offered in the BV421 fluorophore format for flow cytometry applications, providing additional fluorophore flexibility for antigen-specific immune cell monitoring panels.
Quantifiable outcome
- 55% validation rate for dCODE® Klickmer identified antibodies in antibody discovery applications
- +2 more outcomes
Companies that use Immudex
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles4 records
Immudex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability4 records
Feature9 records
Immudex partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Parean BiotechnologiescorePartnership with Parean Biotechnologies, a 10x Genomics Certified Service Provider, providing immune cell phenotyping services using dCODE® reagents. Parean offers expertise in flow cytometry, cell sorting, bulk and single-cell omics sequencing, and data analysis.
- ArdigencorePartnership with Ardigen, a world-leading AI CRO, providing Immune Profiling Multi-Omics Data Analysis Services. Uses advanced platforms and expertise to transform multi-omics datasets generated using dCODE® reagents into ready-to-use scientific insights.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Immudex competitors and assessment
Company assessmentDirect peers
- MBL International (JPT Peptide Technologies): MBL International and its JPT Peptide Technologies division manufacture MHC multimers, tetramers, and peptide-MHC reagents for antigen-specific T cell detection — the most direct technology overlap with Immudex's Dextramer® platform.
- ProImmune: ProImmune offers MHC-peptide tetramers, pentamers, and related immune monitoring reagents for antigen-specific T cell characterization, directly competing in the same reagent category as Immudex.
Broad incumbents
- BioLegend (PerkinElmer): BioLegend (acquired by PerkinElmer/Sciex) is a major flow cytometry reagent vendor offering MHC tetramers and multimer products alongside a much broader catalog of immunology reagents, making it a broad incumbent competitor to Immudex.
- Beckman Coulter (Danaher): Beckman Coulter Life Sciences sells MHC tetramers and a broad flow cytometry reagent portfolio, competing with Immudex in antigen-specific immune cell detection within a much larger parent company's catalog.
- Thermo Fisher Scientific: Thermo Fisher offers MHC Class I and II tetramers and immune monitoring reagents as part of its massive life-science tools catalog, representing a broad incumbent alternative to Immudex's specialty Dextramer® line.
- Cell Signaling Technology (CST): Cell Signaling Technology is a major immunology and cell biology reagent vendor offering flow cytometry products and antibody tools that overlap with Immudex's research reagent customer base, particularly in cancer immunology.
Emerging players
- 10x Genomics: 10x Genomics provides the Chromium single-cell platform that dCODE® Dextramer® integrates with. While not a direct reagent competitor, it is a closely coupled platform player whose product roadmap and pricing directly affects Immudex's multi-omics reagent economics.
- BD Biosciences: BD Biosciences offers the Rhapsody™ single-cell analysis platform that dCODE® Dextramer® (RiO) integrates with. Similar to 10x, BD is a coupled platform provider rather than direct competitor, but its single-cell ecosystem strategy intersects Immudex's multi-omics reagent business.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Immudex social profiles
Digital presenceImmudex compliance and trust
Trust signalCompliance2 records
Immudex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immudex leadership team
Management profileNumber of profiles
Profiles3 records
Immudex funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immudex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immudex
What does Immudex do?
Immudex develops, manufactures, and commercializes Dextramer®-based biological reagents and related custom services for the detection, characterization, and generation of antigen-specific immune cells. Its portfolio spans flow cytometry reagents, DNA-barcoded reagents for NGS and single-cell multi-omics, GMP-grade clinical reagents, and T cell stimulation scaffolds, supported by a custom solutions team that develops new alleles, TCR reagents, and tailored assays for cell therapy developers, vaccine researchers, and academic immunology laboratories.
Is Immudex a public or private company?
Immudex is a private company. It is classified as unknown and is currently operating.
When was Immudex founded?
Immudex was founded in 2009. It employs 11 to 50 people.
Where is Immudex based?
Immudex is headquartered in Virum, Denmark, in the Europe region.
How does Immudex make money?
Four revenue lines are on record. Research Reagent Sales are the primary driver. The others are custom Solutions and Services, clinical-Grade Reagents and xynapse™ Reagent Sales.
Who are Immudex's main competitors?
Direct peers on record are MBL International (JPT Peptide Technologies) and ProImmune. Broad incumbents are BioLegend (PerkinElmer), Beckman Coulter (Danaher), Thermo Fisher Scientific and Cell Signaling Technology (CST). Emerging players are 10x Genomics and BD Biosciences.
Does Immudex have an API?
No public API is recorded for Immudex.
What industry is Immudex in?
Immudex's product category is Immune Monitoring Reagents. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325413 and its SIC code is 2835.